A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Identifieur interne : 003235 ( Main/Exploration ); précédent : 003234; suivant : 003236A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Auteurs : Guy Jerusalem [Belgique] ; Thomas Bachelot [France] ; Carlos Barrios [Brésil] ; Patrick Neven [Belgique] ; Angelo Di Leo [Italie] ; Wolfgang Janni [Allemagne] ; Richard De Boer [Australie]Source :
- Cancer treatment reviews [ 1532-1967 ] ; 2015.
Descripteurs français
- KwdFr :
- Androstadiènes (administration et posologie), Anticorps monoclonaux humanisés (administration et posologie), Antinéoplasiques hormonaux (usage thérapeutique), Bévacizumab, Essais cliniques comme sujet, Femelle, Humains, Inhibiteurs de l'aromatase (administration et posologie), Marqueurs biologiques tumoraux (analyse), Nitriles (administration et posologie), Oestradiol (administration et posologie), Oestradiol (analogues et dérivés), Post-ménopause, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Récepteur ErbB-2 (analyse), Récepteur ErbB-2 (antagonistes et inhibiteurs), Récepteurs des oestrogènes (analyse), Récepteurs des oestrogènes (antagonistes et inhibiteurs), Récepteurs à la progestérone (analyse), Récepteurs à la progestérone (antagonistes et inhibiteurs), Résultat thérapeutique, Sirolimus (administration et posologie), Sirolimus (analogues et dérivés), Survie sans rechute, Sélection de patients, Thérapie moléculaire ciblée (), Triazoles (administration et posologie), Tumeurs du sein (), Tumeurs du sein (mortalité), Tumeurs du sein (traitement médicamenteux), Échec thérapeutique, Évérolimus.
- MESH :
- administration et posologie : Androstadiènes, Anticorps monoclonaux humanisés, Inhibiteurs de l'aromatase, Nitriles, Oestradiol, Sirolimus, Triazoles.
- analogues et dérivés : Oestradiol, Sirolimus.
- analyse : Marqueurs biologiques tumoraux, Récepteur ErbB-2, Récepteurs des oestrogènes, Récepteurs à la progestérone.
- antagonistes et inhibiteurs : Récepteur ErbB-2, Récepteurs des oestrogènes, Récepteurs à la progestérone.
- mortalité : Tumeurs du sein.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Antinéoplasiques hormonaux, Protocoles de polychimiothérapie antinéoplasique.
- Bévacizumab, Essais cliniques comme sujet, Femelle, Humains, Post-ménopause, Résultat thérapeutique, Survie sans rechute, Sélection de patients, Thérapie moléculaire ciblée, Tumeurs du sein, Échec thérapeutique, Évérolimus.
English descriptors
- KwdEn :
- Androstadienes (administration & dosage), Antibodies, Monoclonal, Humanized (administration & dosage), Antineoplastic Agents, Hormonal (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Aromatase Inhibitors (administration & dosage), Bevacizumab, Biomarkers, Tumor (analysis), Breast Neoplasms (chemistry), Breast Neoplasms (drug therapy), Breast Neoplasms (mortality), Clinical Trials as Topic, Disease-Free Survival, Estradiol (administration & dosage), Estradiol (analogs & derivatives), Everolimus, Female, Humans, Molecular Targeted Therapy (methods), Nitriles (administration & dosage), Patient Selection, Postmenopause, Receptor, ErbB-2 (analysis), Receptor, ErbB-2 (antagonists & inhibitors), Receptors, Estrogen (analysis), Receptors, Estrogen (antagonists & inhibitors), Receptors, Progesterone (analysis), Receptors, Progesterone (antagonists & inhibitors), Sirolimus (administration & dosage), Sirolimus (analogs & derivatives), Treatment Failure, Treatment Outcome, Triazoles (administration & dosage).
- MESH :
- chemical , administration & dosage : Androstadienes, Antibodies, Monoclonal, Humanized, Aromatase Inhibitors, Estradiol, Nitriles, Sirolimus, Triazoles.
- chemical , analogs & derivatives : Estradiol, Sirolimus.
- chemical , analysis : Biomarkers, Tumor, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone.
- chemical , antagonists & inhibitors : Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone.
- chemical , therapeutic use : Antineoplastic Agents, Hormonal.
- chemistry : Breast Neoplasms.
- drug therapy : Breast Neoplasms.
- methods : Molecular Targeted Therapy.
- mortality : Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- chemical : Bevacizumab, Clinical Trials as Topic, Disease-Free Survival, Everolimus, Female, Humans, Patient Selection, Postmenopause, Treatment Failure, Treatment Outcome.
Abstract
Disease progression despite existing endocrine therapies remains a major challenge to the effective management of hormone-receptor-positive (HR(+)), human epidermal growth factor receptor-2-negative (HER2(-)), advanced breast cancer. Recent advances in elucidating the molecular mechanisms of disease progression have identified the existence of adaptive "cross-talk" between the estrogen receptor (ER) and various growth factor receptor and intracellular signaling pathways, allowing breast cancer cells to escape the inhibitory effects of endocrine therapy. These findings provide the clinical rationale for enhancing or extending endocrine sensitivity by combining endocrine therapy with a targeted agent against a compensatory pathway. In BOLERO-2, adding the mTOR inhibitor everolimus to endocrine therapy significantly improved progression-free survival (PFS) in patients with HR(+) advanced breast cancer previously treated with nonsteroidal aromatase inhibitor therapy. Notably, PFS benefits were comparable in subgroup analyses of first- and later-line settings. These results contrast with those of the large first-line HORIZON study, wherein adding the mTOR inhibitor temsirolimus to endocrine therapy did not improve PFS. Therefore, it is unclear whether a targeted agent should only be combined with endocrine therapy to restore endocrine sensitivity or whether it may also prevent or delay resistance in hormone-sensitive advanced breast cancer. Numerous additional targeted agents are currently being evaluated in combination with endocrine therapies, including PI3K, cyclin-dependent kinase 4/6, SRC, and histone deacetylase inhibitors. Appropriate patient selection based on prior treatment history will become increasingly important in maximizing the incremental benefit derived from these new agents combined with existing endocrine therapies in HR(+) advanced breast cancer.
DOI: 10.1016/j.ctrv.2014.12.011
PubMed: 25575443
Affiliations:
- Allemagne, Australie, Belgique, Brésil, France, Italie
- Auvergne-Rhône-Alpes, Bade-Wurtemberg, District de Tübingen, Province de Liège, Rhône-Alpes, Victoria (État)
- Liège, Lyon, Melbourne, Ulm
- Université d'Ulm
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003062
- to stream PubMed, to step Curation: 002F81
- to stream PubMed, to step Checkpoint: 002F81
- to stream Ncbi, to step Merge: 002153
- to stream Ncbi, to step Curation: 002153
- to stream Ncbi, to step Checkpoint: 002153
- to stream Main, to step Merge: 003236
- to stream Main, to step Curation: 003235
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.</title>
<author><name sortKey="Jerusalem, Guy" sort="Jerusalem, Guy" uniqKey="Jerusalem G" first="Guy" last="Jerusalem">Guy Jerusalem</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier Universitaire du Sart Tilman Liège and Liège University, Domaine Universitaire du Sart Tilman, B35, 4000 Liège, Belgium. Electronic address: g.jerusalem@chu.ulg.ac.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Centre Hospitalier Universitaire du Sart Tilman Liège and Liège University, Domaine Universitaire du Sart Tilman, B35, 4000 Liège</wicri:regionArea>
<placeName><region type="province" nuts="2">Province de Liège</region>
<settlement type="city">Liège</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bachelot, Thomas" sort="Bachelot, Thomas" uniqKey="Bachelot T" first="Thomas" last="Bachelot">Thomas Bachelot</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Cancérologie de Lyon, Inserm U1052 CNRS 5286, Centre Léon Bérard, 28 rue Laënnec, 69373 LYON cedex 08, Lyon, France. Electronic address: thomas.bachelot@lyon.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre de Recherche en Cancérologie de Lyon, Inserm U1052 CNRS 5286, Centre Léon Bérard, 28 rue Laënnec, 69373 LYON cedex 08, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Barrios, Carlos" sort="Barrios, Carlos" uniqKey="Barrios C" first="Carlos" last="Barrios">Carlos Barrios</name>
<affiliation wicri:level="1"><nlm:affiliation>PUCRS School of Medicine, Padre Chagas 66, 203, Porto Alegre, RS 90 570 080, Brazil. Electronic address: chbe@via-rs.net.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>PUCRS School of Medicine, Padre Chagas 66, 203, Porto Alegre, RS 90 570 080</wicri:regionArea>
<wicri:noRegion>RS 90 570 080</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Neven, Patrick" sort="Neven, Patrick" uniqKey="Neven P" first="Patrick" last="Neven">Patrick Neven</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospitals Leuven, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University Hospitals Leuven, Leuven</wicri:regionArea>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Leo, Angelo" sort="Di Leo, Angelo" uniqKey="Di Leo A" first="Angelo" last="Di Leo">Angelo Di Leo</name>
<affiliation wicri:level="1"><nlm:affiliation>Hospital of Prato, Istituto Toscani Tumori, Prato, Italy. Electronic address: adileo@usl4.toscana.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Hospital of Prato, Istituto Toscani Tumori, Prato</wicri:regionArea>
<wicri:noRegion>Prato</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Janni, Wolfgang" sort="Janni, Wolfgang" uniqKey="Janni W" first="Wolfgang" last="Janni">Wolfgang Janni</name>
<affiliation wicri:level="4"><nlm:affiliation>Women's Hospital, University of Ulm, Prittwitzstr. 43, D-89075 Ulm, Germany. Electronic address: wolfgang.janni@uniklinik-ulm.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Women's Hospital, University of Ulm, Prittwitzstr. 43, D-89075 Ulm</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Ulm</settlement>
<settlement type="city">Ulm</settlement>
</placeName>
<orgName type="university">Université d'Ulm</orgName>
</affiliation>
</author>
<author><name sortKey="De Boer, Richard" sort="De Boer, Richard" uniqKey="De Boer R" first="Richard" last="De Boer">Richard De Boer</name>
<affiliation wicri:level="1"><nlm:affiliation>Royal Melbourne Hospital, Grattan St., Parkville, Melbourne 3050, Australia. Electronic address: Richard.DeBoer@wh.org.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Royal Melbourne Hospital, Grattan St., Parkville, Melbourne 3050</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25575443</idno>
<idno type="pmid">25575443</idno>
<idno type="doi">10.1016/j.ctrv.2014.12.011</idno>
<idno type="wicri:Area/PubMed/Corpus">003062</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003062</idno>
<idno type="wicri:Area/PubMed/Curation">002F81</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F81</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F81</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002F81</idno>
<idno type="wicri:Area/Ncbi/Merge">002153</idno>
<idno type="wicri:Area/Ncbi/Curation">002153</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002153</idno>
<idno type="wicri:Area/Main/Merge">003236</idno>
<idno type="wicri:Area/Main/Curation">003235</idno>
<idno type="wicri:Area/Main/Exploration">003235</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.</title>
<author><name sortKey="Jerusalem, Guy" sort="Jerusalem, Guy" uniqKey="Jerusalem G" first="Guy" last="Jerusalem">Guy Jerusalem</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier Universitaire du Sart Tilman Liège and Liège University, Domaine Universitaire du Sart Tilman, B35, 4000 Liège, Belgium. Electronic address: g.jerusalem@chu.ulg.ac.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Centre Hospitalier Universitaire du Sart Tilman Liège and Liège University, Domaine Universitaire du Sart Tilman, B35, 4000 Liège</wicri:regionArea>
<placeName><region type="province" nuts="2">Province de Liège</region>
<settlement type="city">Liège</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bachelot, Thomas" sort="Bachelot, Thomas" uniqKey="Bachelot T" first="Thomas" last="Bachelot">Thomas Bachelot</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Cancérologie de Lyon, Inserm U1052 CNRS 5286, Centre Léon Bérard, 28 rue Laënnec, 69373 LYON cedex 08, Lyon, France. Electronic address: thomas.bachelot@lyon.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre de Recherche en Cancérologie de Lyon, Inserm U1052 CNRS 5286, Centre Léon Bérard, 28 rue Laënnec, 69373 LYON cedex 08, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Barrios, Carlos" sort="Barrios, Carlos" uniqKey="Barrios C" first="Carlos" last="Barrios">Carlos Barrios</name>
<affiliation wicri:level="1"><nlm:affiliation>PUCRS School of Medicine, Padre Chagas 66, 203, Porto Alegre, RS 90 570 080, Brazil. Electronic address: chbe@via-rs.net.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>PUCRS School of Medicine, Padre Chagas 66, 203, Porto Alegre, RS 90 570 080</wicri:regionArea>
<wicri:noRegion>RS 90 570 080</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Neven, Patrick" sort="Neven, Patrick" uniqKey="Neven P" first="Patrick" last="Neven">Patrick Neven</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospitals Leuven, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University Hospitals Leuven, Leuven</wicri:regionArea>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Leo, Angelo" sort="Di Leo, Angelo" uniqKey="Di Leo A" first="Angelo" last="Di Leo">Angelo Di Leo</name>
<affiliation wicri:level="1"><nlm:affiliation>Hospital of Prato, Istituto Toscani Tumori, Prato, Italy. Electronic address: adileo@usl4.toscana.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Hospital of Prato, Istituto Toscani Tumori, Prato</wicri:regionArea>
<wicri:noRegion>Prato</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Janni, Wolfgang" sort="Janni, Wolfgang" uniqKey="Janni W" first="Wolfgang" last="Janni">Wolfgang Janni</name>
<affiliation wicri:level="4"><nlm:affiliation>Women's Hospital, University of Ulm, Prittwitzstr. 43, D-89075 Ulm, Germany. Electronic address: wolfgang.janni@uniklinik-ulm.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Women's Hospital, University of Ulm, Prittwitzstr. 43, D-89075 Ulm</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Ulm</settlement>
<settlement type="city">Ulm</settlement>
</placeName>
<orgName type="university">Université d'Ulm</orgName>
</affiliation>
</author>
<author><name sortKey="De Boer, Richard" sort="De Boer, Richard" uniqKey="De Boer R" first="Richard" last="De Boer">Richard De Boer</name>
<affiliation wicri:level="1"><nlm:affiliation>Royal Melbourne Hospital, Grattan St., Parkville, Melbourne 3050, Australia. Electronic address: Richard.DeBoer@wh.org.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Royal Melbourne Hospital, Grattan St., Parkville, Melbourne 3050</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Cancer treatment reviews</title>
<idno type="eISSN">1532-1967</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Androstadienes (administration & dosage)</term>
<term>Antibodies, Monoclonal, Humanized (administration & dosage)</term>
<term>Antineoplastic Agents, Hormonal (therapeutic use)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Aromatase Inhibitors (administration & dosage)</term>
<term>Bevacizumab</term>
<term>Biomarkers, Tumor (analysis)</term>
<term>Breast Neoplasms (chemistry)</term>
<term>Breast Neoplasms (drug therapy)</term>
<term>Breast Neoplasms (mortality)</term>
<term>Clinical Trials as Topic</term>
<term>Disease-Free Survival</term>
<term>Estradiol (administration & dosage)</term>
<term>Estradiol (analogs & derivatives)</term>
<term>Everolimus</term>
<term>Female</term>
<term>Humans</term>
<term>Molecular Targeted Therapy (methods)</term>
<term>Nitriles (administration & dosage)</term>
<term>Patient Selection</term>
<term>Postmenopause</term>
<term>Receptor, ErbB-2 (analysis)</term>
<term>Receptor, ErbB-2 (antagonists & inhibitors)</term>
<term>Receptors, Estrogen (analysis)</term>
<term>Receptors, Estrogen (antagonists & inhibitors)</term>
<term>Receptors, Progesterone (analysis)</term>
<term>Receptors, Progesterone (antagonists & inhibitors)</term>
<term>Sirolimus (administration & dosage)</term>
<term>Sirolimus (analogs & derivatives)</term>
<term>Treatment Failure</term>
<term>Treatment Outcome</term>
<term>Triazoles (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Androstadiènes (administration et posologie)</term>
<term>Anticorps monoclonaux humanisés (administration et posologie)</term>
<term>Antinéoplasiques hormonaux (usage thérapeutique)</term>
<term>Bévacizumab</term>
<term>Essais cliniques comme sujet</term>
<term>Femelle</term>
<term>Humains</term>
<term>Inhibiteurs de l'aromatase (administration et posologie)</term>
<term>Marqueurs biologiques tumoraux (analyse)</term>
<term>Nitriles (administration et posologie)</term>
<term>Oestradiol (administration et posologie)</term>
<term>Oestradiol (analogues et dérivés)</term>
<term>Post-ménopause</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Récepteur ErbB-2 (analyse)</term>
<term>Récepteur ErbB-2 (antagonistes et inhibiteurs)</term>
<term>Récepteurs des oestrogènes (analyse)</term>
<term>Récepteurs des oestrogènes (antagonistes et inhibiteurs)</term>
<term>Récepteurs à la progestérone (analyse)</term>
<term>Récepteurs à la progestérone (antagonistes et inhibiteurs)</term>
<term>Résultat thérapeutique</term>
<term>Sirolimus (administration et posologie)</term>
<term>Sirolimus (analogues et dérivés)</term>
<term>Survie sans rechute</term>
<term>Sélection de patients</term>
<term>Thérapie moléculaire ciblée ()</term>
<term>Triazoles (administration et posologie)</term>
<term>Tumeurs du sein ()</term>
<term>Tumeurs du sein (mortalité)</term>
<term>Tumeurs du sein (traitement médicamenteux)</term>
<term>Échec thérapeutique</term>
<term>Évérolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Androstadienes</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Aromatase Inhibitors</term>
<term>Estradiol</term>
<term>Nitriles</term>
<term>Sirolimus</term>
<term>Triazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Estradiol</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers, Tumor</term>
<term>Receptor, ErbB-2</term>
<term>Receptors, Estrogen</term>
<term>Receptors, Progesterone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptor, ErbB-2</term>
<term>Receptors, Estrogen</term>
<term>Receptors, Progesterone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents, Hormonal</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Androstadiènes</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Inhibiteurs de l'aromatase</term>
<term>Nitriles</term>
<term>Oestradiol</term>
<term>Sirolimus</term>
<term>Triazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Oestradiol</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term>
<term>Récepteur ErbB-2</term>
<term>Récepteurs des oestrogènes</term>
<term>Récepteurs à la progestérone</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteur ErbB-2</term>
<term>Récepteurs des oestrogènes</term>
<term>Récepteurs à la progestérone</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques hormonaux</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Bevacizumab</term>
<term>Clinical Trials as Topic</term>
<term>Disease-Free Survival</term>
<term>Everolimus</term>
<term>Female</term>
<term>Humans</term>
<term>Patient Selection</term>
<term>Postmenopause</term>
<term>Treatment Failure</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Bévacizumab</term>
<term>Essais cliniques comme sujet</term>
<term>Femelle</term>
<term>Humains</term>
<term>Post-ménopause</term>
<term>Résultat thérapeutique</term>
<term>Survie sans rechute</term>
<term>Sélection de patients</term>
<term>Thérapie moléculaire ciblée</term>
<term>Tumeurs du sein</term>
<term>Échec thérapeutique</term>
<term>Évérolimus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Disease progression despite existing endocrine therapies remains a major challenge to the effective management of hormone-receptor-positive (HR(+)), human epidermal growth factor receptor-2-negative (HER2(-)), advanced breast cancer. Recent advances in elucidating the molecular mechanisms of disease progression have identified the existence of adaptive "cross-talk" between the estrogen receptor (ER) and various growth factor receptor and intracellular signaling pathways, allowing breast cancer cells to escape the inhibitory effects of endocrine therapy. These findings provide the clinical rationale for enhancing or extending endocrine sensitivity by combining endocrine therapy with a targeted agent against a compensatory pathway. In BOLERO-2, adding the mTOR inhibitor everolimus to endocrine therapy significantly improved progression-free survival (PFS) in patients with HR(+) advanced breast cancer previously treated with nonsteroidal aromatase inhibitor therapy. Notably, PFS benefits were comparable in subgroup analyses of first- and later-line settings. These results contrast with those of the large first-line HORIZON study, wherein adding the mTOR inhibitor temsirolimus to endocrine therapy did not improve PFS. Therefore, it is unclear whether a targeted agent should only be combined with endocrine therapy to restore endocrine sensitivity or whether it may also prevent or delay resistance in hormone-sensitive advanced breast cancer. Numerous additional targeted agents are currently being evaluated in combination with endocrine therapies, including PI3K, cyclin-dependent kinase 4/6, SRC, and histone deacetylase inhibitors. Appropriate patient selection based on prior treatment history will become increasingly important in maximizing the incremental benefit derived from these new agents combined with existing endocrine therapies in HR(+) advanced breast cancer.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Belgique</li>
<li>Brésil</li>
<li>France</li>
<li>Italie</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Bade-Wurtemberg</li>
<li>District de Tübingen</li>
<li>Province de Liège</li>
<li>Rhône-Alpes</li>
<li>Victoria (État)</li>
</region>
<settlement><li>Liège</li>
<li>Lyon</li>
<li>Melbourne</li>
<li>Ulm</li>
</settlement>
<orgName><li>Université d'Ulm</li>
</orgName>
</list>
<tree><country name="Belgique"><region name="Province de Liège"><name sortKey="Jerusalem, Guy" sort="Jerusalem, Guy" uniqKey="Jerusalem G" first="Guy" last="Jerusalem">Guy Jerusalem</name>
</region>
<name sortKey="Neven, Patrick" sort="Neven, Patrick" uniqKey="Neven P" first="Patrick" last="Neven">Patrick Neven</name>
</country>
<country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Bachelot, Thomas" sort="Bachelot, Thomas" uniqKey="Bachelot T" first="Thomas" last="Bachelot">Thomas Bachelot</name>
</region>
</country>
<country name="Brésil"><noRegion><name sortKey="Barrios, Carlos" sort="Barrios, Carlos" uniqKey="Barrios C" first="Carlos" last="Barrios">Carlos Barrios</name>
</noRegion>
</country>
<country name="Italie"><noRegion><name sortKey="Di Leo, Angelo" sort="Di Leo, Angelo" uniqKey="Di Leo A" first="Angelo" last="Di Leo">Angelo Di Leo</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Janni, Wolfgang" sort="Janni, Wolfgang" uniqKey="Janni W" first="Wolfgang" last="Janni">Wolfgang Janni</name>
</region>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="De Boer, Richard" sort="De Boer, Richard" uniqKey="De Boer R" first="Richard" last="De Boer">Richard De Boer</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003235 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003235 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:25575443 |texte= A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25575443" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |